Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp Invests $1.22 Million in Bristol-Myers Squibb Co (NYSE:BMY) Stock

Share on StockTwits

Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,223,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Bristol-Myers Squibb by 2.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock valued at $22,827,000 after acquiring an additional 10,456 shares in the last quarter. Toronto Dominion Bank boosted its holdings in Bristol-Myers Squibb by 19.1% during the second quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock worth $58,813,000 after buying an additional 170,360 shares in the last quarter. Integrated Investment Consultants LLC boosted its holdings in Bristol-Myers Squibb by 1,748.8% during the second quarter. Integrated Investment Consultants LLC now owns 63,468 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 60,035 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Bristol-Myers Squibb by 1.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 123,418 shares of the biopharmaceutical company’s stock worth $6,830,000 after buying an additional 2,323 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Bristol-Myers Squibb by 2.8% during the second quarter. Steward Partners Investment Advisory LLC now owns 43,171 shares of the biopharmaceutical company’s stock worth $2,389,000 after buying an additional 1,161 shares in the last quarter. Hedge funds and other institutional investors own 72.28% of the company’s stock.

BMY has been the subject of a number of research reports. BMO Capital Markets restated a “hold” rating and set a $47.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, June 21st. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Sunday, July 15th. Credit Suisse Group raised their target price on shares of Bristol-Myers Squibb from $58.00 to $61.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. Finally, SunTrust Banks restated a “buy” rating and issued a $67.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, July 31st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $63.13.

BMY stock traded up $0.01 during midday trading on Friday, reaching $57.51. The company had a trading volume of 10,484,764 shares, compared to its average volume of 7,383,813. Bristol-Myers Squibb Co has a 1 year low of $49.96 and a 1 year high of $70.05. The company has a market cap of $101.47 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 1.70 and a beta of 0.98. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. During the same quarter in the prior year, the business posted $0.74 EPS. Bristol-Myers Squibb’s quarterly revenue was up 10.9% on a year-over-year basis. On average, research analysts anticipate that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Stockholders of record on Friday, October 5th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, October 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: What is the S&P 500 Index?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply